Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation.

Kim JH, Nam B, Choi YJ, Kim SY, Lee JE, Sung KJ, Kim WS, Choi CM, Chang EJ, Koh JS, Song JS, Yoon S, Lee JC, Rho JK, Son J.

Cancer Res. 2018 Jun 26. pii: canres.0117.2018. doi: 10.1158/0008-5472.CAN-18-0117. [Epub ahead of print]

PMID:
29945964
2.

Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism.

Cho YR, Lee JH, Kim JH, Lee SY, Yoo S, Jung MK, Kim SJ, Yoo HJ, Pack CG, Rho JK, Son J.

Mol Oncol. 2018 Jun;12(7):1203-1215. doi: 10.1002/1878-0261.12324. Epub 2018 Jun 11.

3.

Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.

Kim DH, Choi YJ, Kim SY, Lee JE, Sung KJ, Sung YH, Kim WS, Kim SE, Ryu HC, Kim JS, Guangying L, Choi CM, Rho JK, Lee JC.

Target Oncol. 2018 May 12. doi: 10.1007/s11523-018-0568-z. [Epub ahead of print]

PMID:
29754184
4.

Correction to Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.

Mah S, Park JH, Jung HY, Ahn K, Choi S, Tae HS, Jung KH, Rho JK, Lee JC, Passerini CG, Fontana D, Hong SS, Hong S.

J Med Chem. 2018 Mar 8;61(5):2131. doi: 10.1021/acs.jmedchem.8b00212. Epub 2018 Feb 22. No abstract available.

PMID:
29470064
5.

Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.

Mah S, Park JH, Jung HY, Ahn K, Choi S, Tae HS, Jung KH, Rho JK, Lee JC, Hong SS, Hong S.

J Med Chem. 2017 Nov 22;60(22):9205-9221. doi: 10.1021/acs.jmedchem.7b01039. Epub 2017 Nov 9.

PMID:
29091425
6.

Radiolabeling and preliminary biodistribution study of 99mTc-labeled antibody-mimetic scaffold protein repebody for initial clearance properties.

Mushtaq S, Rho JK, Kang JA, Lee JJ, Kim JY, Nam YR, Yun SJ, Lee GH, Park SH, Lee DE, Kim HS.

Bioorg Med Chem Lett. 2017 Nov 15;27(22):5060-5064. doi: 10.1016/j.bmcl.2017.09.047. Epub 2017 Sep 25.

PMID:
29042166
7.

Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced apoptosis.

Kim SY, Park S, Yoo S, Rho JK, Jun ES, Chang S, Kim KK, Kim SC, Kim I.

Oncotarget. 2017 May 12;8(37):61057-61071. doi: 10.18632/oncotarget.17841. eCollection 2017 Sep 22.

8.

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement.

Choi SH, Kim DH, Choi YJ, Kim SY, Lee JE, Sung KJ, Kim WS, Choi CM, Rho JK, Lee JC.

Oncotarget. 2017 May 8;8(35):58771-58780. doi: 10.18632/oncotarget.17680. eCollection 2017 Aug 29.

9.

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

Kwon BS, Park JH, Kim WS, Song JS, Choi CM, Rho JK, Lee JC.

Tuberc Respir Dis (Seoul). 2017 Apr;80(2):187-193. doi: 10.4046/trd.2017.80.2.187. Epub 2017 Mar 31.

10.

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.

Choi YJ, Kim JH, Rho JK, Kim JS, Choi CM, Kim WS, Son J, Lee JC.

Oncol Rep. 2017 Apr;37(4):2201-2208. doi: 10.3892/or.2017.5482. Epub 2017 Mar 1.

PMID:
28260071
11.

Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.

Hwang DW, So KS, Kim SC, Park KM, Lee YJ, Kim SW, Choi CM, Rho JK, Choi YJ, Lee JC.

Pancreas. 2017 Apr;46(4):575-581. doi: 10.1097/MPA.0000000000000780.

PMID:
28196025
12.

Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.

Park S, Hur JY, Lee KY, Lee JC, Rho JK, Shin SH, Choi CM.

Clin Chem Lab Med. 2017 Aug 28;55(10):1489-1495. doi: 10.1515/cclm-2016-0302.

PMID:
28195541
13.

Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.

Rho JK, Lee IY, Choi YJ, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, Baek IJ, Lee JY, Ha CH, Sung YH, Kim JK, Kim WS, Song JS, Kim CH, Bivona TG, Lee JC.

Cancer Res. 2017 Mar 1;77(5):1200-1211. doi: 10.1158/0008-5472.CAN-16-2432. Epub 2017 Jan 12.

14.

Genetically engineered and self-assembled oncolytic protein nanoparticles for targeted cancer therapy.

Lee JJ, Kang JA, Ryu Y, Han SS, Nam YR, Rho JK, Choi DS, Kang SW, Lee DE, Kim HS.

Biomaterials. 2017 Mar;120:22-31. doi: 10.1016/j.biomaterials.2016.12.014. Epub 2016 Dec 19.

PMID:
28024232
15.

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.

Hwang JA, Lee JY, Kim WS, Song JS, Rho JK, Choi CM, Lee JC.

Clin Lung Cancer. 2016 Nov;17(6):573-580.e1. doi: 10.1016/j.cllc.2016.05.018. Epub 2016 Jun 11.

PMID:
27378173
16.

Gallic acid induces apoptosis in EGFR-mutant non-small cell lung cancers by accelerating EGFR turnover.

Nam B, Rho JK, Shin DM, Son J.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4571-4575. doi: 10.1016/j.bmcl.2016.08.083. Epub 2016 Aug 27.

PMID:
27597244
17.

Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Phan AN, Hua TN, Kim MK, Vo VT, Choi JW, Kim HW, Rho JK, Kim KW, Jeong Y.

Oncotarget. 2016 Aug 23;7(34):54702-54713. doi: 10.18632/oncotarget.10581.

18.

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.

Park S, Kim HJ, Choi CM, Lee DH, Kim SW, Lee JS, Kim WS, Choi SH, Rho JK, Lee JC.

BMC Cancer. 2016 Jul 7;16:417. doi: 10.1186/s12885-016-2457-0.

19.

Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Park JH, Choi YJ, Kim SY, Lee JE, Sung KJ, Park S, Kim WS, Song JS, Choi CM, Sung YH, Rho JK, Lee JC.

Oncotarget. 2016 Apr 19;7(16):22005-15. doi: 10.18632/oncotarget.8013.

20.

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement.

Kim HJ, Lee KY, Kim YW, Choi YJ, Lee JE, Choi CM, Baek IJ, Rho JK, Lee JC.

BMC Cancer. 2015 Jul 29;15:553. doi: 10.1186/s12885-015-1543-z.

21.

The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer.

Son Y, Lee HJ, Rho JK, Chung SY, Lee CG, Yang K, Kim SH, Lee M, Shin IS, Kim JS.

BMC Pulm Med. 2015 Jul 5;15:68. doi: 10.1186/s12890-015-0055-6.

22.

An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib.

Kwon T, Rho JK, Lee JC, Park YH, Shin HJ, Cho S, Kang YK, Kim BY, Yoon DY, Yu DY.

Exp Mol Med. 2015 May 29;47:e165. doi: 10.1038/emm.2015.24.

23.

Development of fluorescent probes that bind and stain amyloid plaques in Alzheimer's disease.

Jung SJ, Park SH, Lee EJ, Park JH, Kong YB, Rho JK, Hur MG, Yang SD, Park YD.

Arch Pharm Res. 2015 Nov;38(11):1992-8. doi: 10.1007/s12272-015-0617-4. Epub 2015 May 27.

PMID:
26012373
24.

AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.

Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM.

PLoS One. 2015 Mar 17;10(3):e0119832. doi: 10.1371/journal.pone.0119832. eCollection 2015.

25.

AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.

So KS, Rho JK, Choi YJ, Kim SY, Choi CM, Chun YJ, Lee JC.

Anticancer Res. 2015 Mar;35(3):1537-42.

PMID:
25750308
26.

Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.

Kim GW, Song JS, Choi CM, Rho JK, Kim SY, Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, Kim SW, Lee DH, Lee JC.

Lung Cancer. 2015 May;88(2):139-46. doi: 10.1016/j.lungcan.2015.01.023. Epub 2015 Feb 12.

PMID:
25724261
27.

Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.

So KS, Kim CH, Rho JK, Kim SY, Choi YJ, Song JS, Kim WS, Choi CM, Chun YJ, Lee JC.

PLoS One. 2014 Dec 8;9(12):e114000. doi: 10.1371/journal.pone.0114000. eCollection 2014.

28.

Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.

Kim HC, Song JS, Lee JC, Lee DH, Kim SW, Lee JS, Kim WS, Rho JK, Kim SY, Choi CM.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6743-51. eCollection 2014.

29.

Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children.

Lim SM, Yoo CJ, Han JW, Cho YJ, Kim SH, Ahn JB, Rha SY, Shin SJ, Chung HC, Yang WI, Shin KH, Rho JK, Kim HS.

Cancer Res Treat. 2015 Jan;47(1):9-17. doi: 10.4143/crt.2013.157. Epub 2014 Aug 21.

30.

Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.

Choi DY, You S, Jung JH, Lee JC, Rho JK, Lee KY, Freeman MR, Kim KP, Kim J.

Proteomics. 2014 Aug;14(16):1845-56. doi: 10.1002/pmic.201400008. Epub 2014 Jul 16.

PMID:
24946052
31.

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, Kim SW, Lee DH, Lee JC.

BMC Cancer. 2013 Dec 27;13:606. doi: 10.1186/1471-2407-13-606.

32.

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.

Choi YJ, Park GM, Rho JK, Kim SY, So GS, Kim HR, Choi CM, Lee JC.

PLoS One. 2013 Dec 5;8(12):e81393. doi: 10.1371/journal.pone.0081393. eCollection 2013.

33.

Biodistribution of (99m)tc tricarbonyl glycine oligomers.

Jang BS, Lee JS, Rho JK, Park SH.

Toxicol Res. 2012 Dec;28(4):235-40. doi: 10.5487/TR.2012.28.4.235.

34.

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.

Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, Lee JC.

Cancer Res. 2014 Jan 1;74(1):253-62. doi: 10.1158/0008-5472.CAN-13-1103. Epub 2013 Oct 28.

35.

Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor.

Chang Y, Kim SY, Choi YJ, So KS, Rho JK, Kim WS, Lee JC, Chung JH, Choi CM.

Tuberc Respir Dis (Seoul). 2013 Sep;75(3):95-103. doi: 10.4046/trd.2013.75.3.95. Epub 2013 Sep 30.

36.

Simultaneous inhibition of rhamnolipid and polyhydroxyalkanoic acid synthesis and biofilm formation in Pseudomonas aeruginosa by 2-bromoalkanoic acids: effect of inhibitor alkyl-chain-length.

Gutierrez M, Choi MH, Tian B, Xu J, Rho JK, Kim MO, Cho YH, Yoon SC.

PLoS One. 2013 Sep 4;8(9):e73986. doi: 10.1371/journal.pone.0073986. eCollection 2013.

37.

Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.

Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC.

Mol Oncol. 2013 Dec;7(6):1093-102. doi: 10.1016/j.molonc.2013.08.001. Epub 2013 Aug 20.

38.

Cranofacial osteosarcoma: Single institutional experience in Korea.

Lim S, Lee S, Rha SY, Rho JK.

Asia Pac J Clin Oncol. 2016 Mar;12(1):e149-53. doi: 10.1111/ajco.12072. Epub 2013 May 29.

PMID:
23718845
39.

Sensitive detection of EML4-ALK fusion oncoprotein of lung cancer by in situ proximity ligation assay.

Rho JK, Lee H, Park CS, Choi CM, Lee JC.

Clin Chem Lab Med. 2013 Sep;51(9):1843-8. doi: 10.1515/cclm-2013-0044.

PMID:
23612660
40.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.

Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.

41.

Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.

Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, Lee JS, Lee SJ, Lee JC, Park MJ.

Oncogene. 2013 Jan 10;32(2):209-21. doi: 10.1038/onc.2012.37. Epub 2012 Feb 27.

PMID:
22370645
42.

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM.

Nat Med. 2011 Dec 11;18(1):74-82. doi: 10.1038/nm.2577. Erratum in: Nat Med. 2014 Jan;20(1):103.

43.

Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.

Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK, Rha SY.

Oncology. 2011;81(3-4):175-83. doi: 10.1159/000333440. Epub 2011 Nov 3.

PMID:
22057187
44.

The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells.

Rho JK, Choi YJ, Choi YR, Kim SY, Choi SJ, Choi CM, Na II, Lee JC.

Oncol Res. 2011;19(10-11):471-8.

PMID:
22715590
45.

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.

Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, Choi YJ, Kim HR, Kim CH, Lee JC.

Lung Cancer. 2011 Aug;73(2):176-82. doi: 10.1016/j.lungcan.2010.11.011. Epub 2010 Dec 17.

PMID:
21168239
46.

Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.

Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, Woo SK, Kim HR, Kim CH, Choi CM, Lee JC.

Mol Cancer Ther. 2010 Dec;9(12):3233-43. doi: 10.1158/1535-7163.MCT-10-0625.

47.

Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.

Kook EH, Kim YM, Kim HT, Koh JS, Choi YJ, Rho JK, Kim HR, Kim CH, Lee JC.

Oncol Res. 2010;18(9):445-51.

PMID:
20524402
48.
49.

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.

Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8. doi: 10.1007/s00280-009-1174-7. Epub 2009 Nov 18.

PMID:
19921194
50.

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.

Mol Cancer Res. 2009 Oct;7(10):1736-43. doi: 10.1158/1541-7786.MCR-08-0504. Epub 2009 Oct 6.

Supplemental Content

Support Center